...

Conference Report

Advances in Small-Cell Lung Cancer and the Role of Marker Analysis in Advanced NSCLC

Source: CCO Independent Conference Coverage of the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Advances in Small-Cell Lung Cancer and the Role of Marker Analysis in Advanced NSCLC


Faculty:

Paul A. Bunn, Jr., MDFred R. Hirsch, MD, PhDCorey J. Langer, MD, FACP
  • Paul A. Bunn, Jr., MD
  • Fred R. Hirsch, MD, PhD
  • Corey J. Langer, MD, FACP

CREDIT INFORMATION

Release Date: March 13, 2009

Expiration Date: March 12, 2010


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Begin the Conference Report

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review new data on the efficacy and safety of accelerated hyperfractionated radiation therapy for the treatment of small-cell lung cancer
  • Summarize recent findings on the role of biomarkers in predicting response to EGFR-targeted agents in advanced non-small-cell lung cancer
  • Discuss the latest data on the prognostic value of biomarkers for predicting risk of recurrence following resection of early-stage non-small-cell lung cancer

Topics covered include:

  • Accelerated Hyperfractionated Radiation Therapy vs Once-Daily Radiation Therapy in Limited Stage Small-Cell Lung Cancer
  • IASLC Staging and Small-Cell Lung Cancer
  • Biomarker Analysis as Potential Predictor of Benefit With First-line Cetuximab in Advanced NSCLC
  • Prospective EGFR Biomarker Selection for Erlotinib in First-Line NSCLC
  • Racial Differences in EGFR Genetic Profile
  • Biomarker Expression in Patients With Resected NSCLC
  • Prognostic Importance of PTEN and Other Gene Copy Numbers in Resectable NSCLC
  • Conclusions

Abstract
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

This program is supported by educational grants from:

Educational grants support only the CME-certified components of this program.